Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 4/20 | 0.45 |
| ▸ | DRD2 | P14416 | 2/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.43 |
| ▸ | HTR2C | P28335 | 2/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26004281 | 1.00 | DRD4 (0.45) | DRD4DRD2SIGMAR1HTR2CDRD3 | |
| SCHEMBL26004283 | 0.91 | DRD4 (0.43) | DRD4DRD2SIGMAR1HTR2CDRD3 | |
| SCHEMBL25359584 | 0.91 | DRD4 (0.43) | DRD4DRD2SIGMAR1HTR2CDRD3 | |
| SCHEMBL26012439 | 0.89 | DRD4 (0.51) | DRD4DRD2SIGMAR1HTR2CDRD3 | |
| SCHEMBL25359488 | 0.89 | DRD4 (0.51) | DRD4DRD2SIGMAR1HTR2CDRD3 | |
| SCHEMBL26004354 | 0.89 | SIGMAR1 (0.49) | SIGMAR1 | |
| SCHEMBL26013583 | 0.86 | SIGMAR1 (0.46) | DRD4DRD2SIGMAR1MEN1KMT2A | |
| SCHEMBL26004506 | 0.86 | DRD4 (0.42) | DRD4DRD2SIGMAR1HTR2CDRD3 | |
| SCHEMBL26004218 | 0.85 | DRD4 (0.45) | DRD4DRD2SIGMAR1HTR2CDRD3 | |
| SCHEMBL25356312 | 0.84 | MAPK1 (0.45) | DRD4DRD2SIGMAR1HTR2CDRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250195483-A1 | SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMA (US) | 2025-06-19 | — | — | US | disclosed |
| WO-2023154314-A1 | SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195483-A1 | SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, PNLIP, SAAL1 | DRD4 1614/4885DRD2 1882/4885SIGMAR1 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.